199 related articles for article (PubMed ID: 30553721)
1. Increasing complexity and interactions of oxidative stress in chronic respiratory diseases: An emerging need for novel drug delivery systems.
Dua K; Malyla V; Singhvi G; Wadhwa R; Krishna RV; Shukla SD; Shastri MD; Chellappan DK; Maurya PK; Satija S; Mehta M; Gulati M; Hansbro N; Collet T; Awasthi R; Gupta G; Hsu A; Hansbro PM
Chem Biol Interact; 2019 Feb; 299():168-178. PubMed ID: 30553721
[TBL] [Abstract][Full Text] [Related]
2. Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review.
Xu Y; Liu H; Song L
J Nanobiotechnology; 2020 Oct; 18(1):145. PubMed ID: 33076918
[TBL] [Abstract][Full Text] [Related]
3. Oxidative stress and lung inflammation in airways disease.
MacNee W
Eur J Pharmacol; 2001 Oct; 429(1-3):195-207. PubMed ID: 11698041
[TBL] [Abstract][Full Text] [Related]
4. Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases.
Mehta M; Deeksha ; Tewari D; Gupta G; Awasthi R; Singh H; Pandey P; Chellappan DK; Wadhwa R; Collet T; Hansbro PM; Kumar SR; Thangavelu L; Negi P; Dua K; Satija S
Chem Biol Interact; 2019 Aug; 308():206-215. PubMed ID: 31136735
[TBL] [Abstract][Full Text] [Related]
5. Delivery systems for biopharmaceuticals. Part II: Liposomes, Micelles, Microemulsions and Dendrimers.
Silva AC; Lopes CM; Lobo JM; Amaral MH
Curr Pharm Biotechnol; 2015; 16(11):955-65. PubMed ID: 26278524
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of airway targeted PLGA nanoparticles for drug delivery in obstructive lung diseases.
Vij N
Methods Mol Biol; 2012; 906():303-10. PubMed ID: 22791443
[TBL] [Abstract][Full Text] [Related]
7. Multi-drug resistant Mycobacterium tuberculosis & oxidative stress complexity: Emerging need for novel drug delivery approaches.
Dua K; Rapalli VK; Shukla SD; Singhvi G; Shastri MD; Chellappan DK; Satija S; Mehta M; Gulati M; Pinto TJA; Gupta G; Hansbro PM
Biomed Pharmacother; 2018 Nov; 107():1218-1229. PubMed ID: 30257336
[TBL] [Abstract][Full Text] [Related]
8. Targeting neutrophils using novel drug delivery systems in chronic respiratory diseases.
Chellappan DK; Yee LW; Xuan KY; Kunalan K; Rou LC; Jean LS; Ying LY; Wie LX; Chellian J; Mehta M; Satija S; Singh SK; Gulati M; Dureja H; Da Silva MW; Tambuwala MM; Gupta G; Paudel KR; Wadhwa R; Hansbro PM; Dua K
Drug Dev Res; 2020 Jun; 81(4):419-436. PubMed ID: 32048757
[TBL] [Abstract][Full Text] [Related]
9. Role of enzymatic free radical scavengers in management of oxidative stress in autoimmune disorders.
Srivastava S; Singh D; Patel S; Singh MR
Int J Biol Macromol; 2017 Aug; 101():502-517. PubMed ID: 28342757
[TBL] [Abstract][Full Text] [Related]
10. Different approaches in the treatment of obstructive pulmonary diseases.
Kabir ER; Morshed N
Eur J Pharmacol; 2015 Oct; 764():306-317. PubMed ID: 26172082
[TBL] [Abstract][Full Text] [Related]
11. Micro- and nanocarrier-mediated lung targeting.
Kurmi BD; Kayat J; Gajbhiye V; Tekade RK; Jain NK
Expert Opin Drug Deliv; 2010 Jul; 7(7):781-94. PubMed ID: 20560777
[TBL] [Abstract][Full Text] [Related]
12. Combination of urea-crosslinked hyaluronic acid and sodium ascorbyl phosphate for the treatment of inflammatory lung diseases: An in vitro study.
Fallacara A; Busato L; Pozzoli M; Ghadiri M; Ong HX; Young PM; Manfredini S; Traini D
Eur J Pharm Sci; 2018 Jul; 120():96-106. PubMed ID: 29723596
[TBL] [Abstract][Full Text] [Related]
13. Antioxidant and anti-inflammatory effects of resveratrol in airway disease.
Wood LG; Wark PA; Garg ML
Antioxid Redox Signal; 2010 Nov; 13(10):1535-48. PubMed ID: 20214495
[TBL] [Abstract][Full Text] [Related]
14. Co-spray dried resveratrol and budesonide inhalation formulation for reducing inflammation and oxidative stress in rat alveolar macrophages.
Trotta V; Lee WH; Loo CY; Young PM; Traini D; Scalia S
Eur J Pharm Sci; 2016 Apr; 86():20-8. PubMed ID: 26944422
[TBL] [Abstract][Full Text] [Related]
15. [Cyto-oxidant markers of inflammation in assessing the efficacy of differentiating therapy of severe obstructive pulmonary diseases].
Grinshteĭn IuI; Shestovitskiĭ VA; Kuligina-Maksimova AV; Cherkashina II; Aristov AI
Klin Med (Mosk); 2003; 81(7):28-31. PubMed ID: 12934307
[TBL] [Abstract][Full Text] [Related]
16. Lipid-based carriers: manufacturing and applications for pulmonary route.
Jaafar-Maalej C; Elaissari A; Fessi H
Expert Opin Drug Deliv; 2012 Sep; 9(9):1111-27. PubMed ID: 22724618
[TBL] [Abstract][Full Text] [Related]
17. Recent Trends in Clinical Trials Related to Carrier-Based Drugs.
Tagami T; Ozeki T
J Pharm Sci; 2017 Sep; 106(9):2219-2226. PubMed ID: 28259767
[TBL] [Abstract][Full Text] [Related]
18. Novel drug delivery systems for NSAIDs in management of rheumatoid arthritis: An overview.
Thakur S; Riyaz B; Patil A; Kaur A; Kapoor B; Mishra V
Biomed Pharmacother; 2018 Oct; 106():1011-1023. PubMed ID: 30119166
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary delivery of anti-inflammatory agents.
Ali ME; McConville JT; Lamprecht A
Expert Opin Drug Deliv; 2015 Jun; 12(6):929-45. PubMed ID: 25534260
[TBL] [Abstract][Full Text] [Related]
20. Interactions with the macrophages: An emerging targeted approach using novel drug delivery systems in respiratory diseases.
Mehta M; Deeksha ; Sharma N; Vyas M; Khurana N; Maurya PK; Singh H; Andreoli de Jesus TP; Dureja H; Chellappan DK; Gupta G; Wadhwa R; Collet T; Hansbro PM; Dua K; Satija S
Chem Biol Interact; 2019 May; 304():10-19. PubMed ID: 30849336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
